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Abstract
Background: Conditional gene knockout (cKO) mediated by the Cre/LoxP system is indispensable for exploring
gene functions in mice. However, a major limitation of this method is that gene KO is not reversible. A number of
methods have been developed to overcome this, but each method has its own limitations.
Results: We describe a simple method we have named LOFT [LoxP-flippase (FLP) recognition target (FRT) Trap],
which is capable of reversible cKO and free of the limitations associated with existing techniques. This method
involves two alleles of a target gene: a standard floxed allele, and a multi-functional allele bearing an FRT-flanked
gene-trap cassette, which inactivates the target gene while reporting its expression with green fluorescent protein
(GFP); the trapped allele is thus a null and GFP reporter by default, but is convertible into a wild-type allele. The
floxed and trapped alleles can typically be generated using a single construct bearing a gene-trap cassette doubly
flanked by LoxP and FRT sites, and can be used independently to achieve conditional and constitutive gene KO,
respectively. More importantly, in mice bearing both alleles and also expressing the Cre and FLP recombinases,
sequential function of the two enzymes should lead to deletion of the target gene, followed by restoration of its
expression, thus achieving reversible cKO. LOFT should be generally applicable to mouse genes, including the
growing numbers of genes already floxed; in the latter case, only the trapped alleles need to be generated to
confer reversibility to the pre-existing cKO models. LOFT has other applications, including the creation and reversal
of hypomorphic mutations. In this study we proved the principle of LOFT in the context of T-cell development, at
a hypomorphic allele of Baf57/Smarce1 encoding a subunit of the chromatin-remodeling Brg/Brahma-associated
factor (BAF) complex. Interestingly, the FLP used in the current work caused efficient reversal in peripheral T cells
but not thymocytes, which is advantageous for studying developmental epigenetic programming of T-cell
functions, a fundamental issue in immunology.
Conclusions: LOFT combines well-established basic genetic methods into a simple and reliable method for
reversible gene targeting, with the flexibility of achieving traditional constitutive and conditional KO.
Background
Conventional gene knockout (KO) technologies such as
LoxP/Cre-mediated conditional gene KO (cKO) are widely
used for discovering gene functions. A key limitation of
these methods is that the KO is irreversible. It is therefore
impossible to determine if, for example, the malignancies
and neurological disorders reported in p53 and MeCP2
KO mice, respectively, can be cured by restoring gene
functions, a question of obvious clinical relevance. Because
the KO in the original mouse models is not reversible, spe-
cial strains have to be generated to address these ques-
tions, which entails substantial amounts of work [1-3].
Reversible KO would also be invaluable for studying epige-
netic programming, a central issue in developmental
biology. Specifically, during lineage development, transient
action of environmental cues is thought to irreversibly
modify (or ‘program’) the epigenetic states of target genes
in the developing cells, such that the altered epigenetic
states can persist and be propagated to mature progeny
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cells without the continuous presence of the initiating cues
[4]. Defining the role of a gene in developmental program-
ming requires deleting the gene in immature cells and
analyzing the resultant defects in mature cells, but the
gene controlling developmental programming may also be
expressed and functioning in mature cells, which compli-
cates data interpretation, given that conventional KO
strategy is not reversible. For example, deleting the chro-
matin-remodeling factor Mi-2b in immature T cells
impairs proliferation of mature T cells [5], but because
Mi-2b is expressed not only in immature but also in
mature T cells, it is unclear if the proliferation defect
reflects a developmental role of Mi-2b. The only way to
directly address such an issue is to eliminate the protein in
immature cells. and then restore its expression in mature
cells.
Multiple methods have been devised to achieve reversi-
ble gene regulation, but each has limitations. In one
method, endogenous genes are modified so that their
expression is now driven by tetracycline-regulated artificial
transcription activators expressed from the endogenous
regulatory elements, thus allowing for reversible gene reg-
ulation, but it is difficult to recapitulate the expression
levels of the endogenous genes with the synthetic activa-
tors [6-9]. In an alternative method, tetracycline-controlled
transcriptional silencer (tTS), a tetracycline-regulated tran-
scription repressor, has been successfully used to reversi-
bly inhibit the expression of Hoxa2 and Htr1a, but
whether this method is generally applicable to other genes
remains unclear, and furthermore, the only tTS transgenic
line currently available expresses tTS in various tissues,
and is hence unsuitable for tissue-specific inhibition. Regu-
lated expression of small hairpin RNA has also been used
for reversible gene repression, but the repression is usually
incomplete [2]. Finally, transcription stop sequences or
gene-trap cassettes, which are removable/inactivable, can
be inserted into target genes, leading to constitutive KO
that can be conditionally rescued, but this strategy is not
suitable for conditional induction of gene KO [1,3,10,11].
In this paper, we describe a straightforward and robust
method for reversible cKO without these limitations. The
method, which we dub LOFT [LoxP-flippase (FLP)
recognition target (FRT) Trap], combines cKO with gene
trapping, a well-established method for insertional muta-
genesis [12-16]. In its simplest form, a gene-trap cassette
consists of a promoterless selectable marker flanked by
a splice acceptor (SA) and a polyadenylation (pA)
sequence. When inserted into an intron of an expressed
gene, the SA captures the upstream exon while the pA
sequence truncates the transcript, thus producing a
fusion protein between the N-terminus of the trapped
protein and the selectable marker. Thus, gene traps
simultaneously inactivate and report the expression of
the trapped gene. Gene trapping can be made conditional
by flanking gene-trap modules with LoxP/FRT sites
[10,11,17]. LOFT combines Cre-catalyzed cKO with FLP-
catalyzed reversible trapping to achieve reversible cKO.
LOFT can also be used to create conventional KO mice.
We report a proof-of-concept study using the gene
encoding Brg/Brahma-associated factor (BAF)57, a subu-
nit of the chromatin-remodeling BAF complex.
The BAF complex, a prototypical mammalian ATP-
dependent chromatin remodeler complex (CRC), is widely
expressed, and plays diverse, often tissue-specific roles in
gene regulation [18-20]. Although called ATP-dependent
CRC, the complex can also regulate target genes without
using the classic ATP-dependent chromatin-remodeling
activity [21]. Indeed, although the complex consists of
more than ten subunits, a group of four core subunits,
including the catalytic subunit Brahma-related gene (BRG)
1, is fully sufficient to reconstitute ATP-dependent chro-
matin-remodeling in vitro [22]. The functions of the
remaining accessory subunits are poorly understood, but
may contribute to the ATP-independent functions of the
BAF complex and/or modulate the classic remodeling
activity of the BAF complex. The 57 kDa high mobility
group (HMG) protein BAF57 (also known as SMARCE1;
Switch/sucrose non-fermentable (SWI/SWF) related
matrix-associated actin-dependent regulator of chromatin
subfamily E member 1) is the first known accessory subu-
nit [23]. BAF57 is important for T -cell development in
mice [24], and for regulating apoptosis [25], the cell cycle
[26] and functions of the androgen and estrogen receptors
[27-29] in tumor lines. Furthermore, BAF57 is strongly
expressed in human endometrial carcinoma, and serves as
a marker of poor prognosis [30].
We are interested in further studying the roles of BAF57
in T- cell development in the thymus, which is arguably the
best-defined ontogenetic system in vertebrates [31]. The
earliest thymocytes are double-negative (DN) cells lacking
the antigen coreceptor CD4 or CD8. These cells undergo
extensive proliferation, and express both CD4 and CD8
to become double-positive (DP) cells. DP cells bifurcate
into CD4 helper and CD8 cytotoxic cells, the two major
subsets of T lymphocytes in the adaptive immune system,
which are marked by CD4 and CD8 expression, respec-
tively. We previously explored the role of BAF57 in T cells
using a BAF57 dominant-negative mutant. BAF57 is a pro-
tein of 411 amino acids (aa) consisting of several conserved
domains, including the N-terminal proline-rich domain (23
aa) with unknown functions, the HMG domain (aa 66 to
133) that binds DNA, a domain rich in Asp, His, Leu and
Ile (NHRKI), and the C-terminal domain rich in acidic resi-
dues [32]. The functions of these domains are unknown
except for the DNA-binding of the HMG domain [23].
We found that thymocyte-specific expression of a domi-
nant-negative mutant of BAF57 lacking the N-terminal 133
aa including the HMG causes reciprocal CD4/CD8
Chaiyachati et al. BMC Biology 2012, 10:96
http://www.biomedcentral.com/1741-7007/10/96
Page 2 of 13
misregulation during T-cell development, but the mutant
does not significantly impair production or function of
mature T cells [24,33]. Because the dominant-negative
mutation impairs only a specific aspect of BAF57 function,
the roles of BAF57 in T cells remain incompletely under-
stood. In particular, it is unclear if BAF57, acting in thymo-
cytes, can epigenetically program the function of mature




cKO followed by conditional restoration of gene expres-
sion is achieved with a pair of alleles of a target gene: a
floxed allele and a reversibly trapped allele that is a null by
default but can be conditionally converted to a wild-type
(WT) allele. The latter allele is designated ΔR, where R
denotes ‘reversible’ (Figure 1). The key component of the
ΔR allele is a gene-trap cassette consisting of the neomycin
phosphotransferase (Neo) and an Ires-green fluorescent
protein (GFP) construct. This cassette is inserted into an
intron, thus capturing the upstream exon to produce a
fusion protein between the N-terminus of the target pro-
tein and the neomycin phosphotransferase, the former
moiety being inactive, and the latter serving as the selec-
tion marker for successfully targeted embryonic stem (ES)
cells if the target gene is expressed in those cells. In addi-
tion, GFP is co-expressed with the fusion protein, which
reports the expression pattern of the target gene. Impor-
tantly, the gene-trapping cassette is flanked by FLP recom-
bination target (FRT) sites, allowing for conditional
excision of the cassette in the presence of active FLP. The
removal of the gene-trapping cassette restores the expres-
sion of full-length protein, concomitant with the loss of
GFP expression. The floxed and ΔR alleles can be used
separately to achieve conditional and constitutive gene
KO, respectively, but in combination, they allow for rever-
sible cKO: in mice bearing both alleles and also expressing
conditional Cre and FLP, sequential function of the two
enzymes will lead to target gene knockout followed by
restoration of its expression, and this process can be moni-
tored by the loss of GFP expression (Figure 1). The con-
struct depicted in Figure 1 is not suitable for genes not
expressed in ES cells. In such cases, one may delete the
Neo-Ires sequence in the vector and insert a Neo expres-
sion cassette (containing a promoter active in the ES cells)
between GFP-pA sequence and the 3’ FRT, thus turning
the promoter-trapping vector into a simple conventional
knock-in construct. Of note, although the major applica-
tion of LOFT is likely to be reversible cKO, variations of
the theme are readily conceivable. For example, if excision
of the floxed sequence leads to the production of a dele-
tion mutant rather than to elimination of the entire
protein, then LOFT may be used to reverse the effects of
such hypomorphic mutations, as described below.
Generation of Baf57F and Baf57ΔR
Our goal was to study the potential roles of BAF57 in
developmental programming of T cells, which required
deleting BAF57 in immature T cells, followed by the rever-
sal of the KO in mature T cells. Because our previous stu-
dies involving BRG1 suggests that complete elimination of
BAF57 might block T-cell development and make the
experiment unfeasible [21,34], we sought to reduce rather
than eliminate BAF57 expression. To this end, we floxed
exons 2 and 3, which encode the first 18 residues of
BAF57, and named the resulting allele BAF57F (Figure 2).
Deleting the two exons would be expected to cause
expression of a truncated BAF57 protein that starts with a
methionine encoded by an ATG in exon 4. Because the
ATG in exon 4 is not embedded in the Kozak consensus
sequence, the mutant should be expressed at lower levels
than the WT. In addition, the residual protein might not
be fully active, given that it lacks the bulk of the conserved
proline-rich domain. Thus, we would expect Baf57F to be
a conditional hypomorphic allele.
Baf57F and Baf57ΔR were generated with a single target-
ing vector by exploiting crossing-over site variability dur-
ing homologous recombination (Figure 2) [35-37]. To
facilitate the generation of Baf57ΔR lacking the 5’ LoxP
site, we used a short (0.5 kb) left arm upstream of the 5’
LoxP site. This was used to ensure that during homolo-
gous recombination between the left arm and the endo-
genous sequence, the crossing over could take place not
only upstream of the 5’ LoxP site, leading to its incorpora-
tion into the endogenous gene, but also downstream of
the LoxP site, preventing its incorporation. The targeted
allele retaining the 5’ LoxP site (Baf57Int) can be converted
to Baf57F after FLP-mediated excision of the gene-trap
cassette from the germline, whereas the allele lacking the
5’ LoxP site is Cre-resistant and acts as Baf57ΔR.
We recovered both Baf57Int and Baf57ΔR after screen-
ing only 20 ES cell clones, confirming that the targeting
method, called ‘targeted trapping’ [38], is extremely effi-
cient (Figure 3). Of note, only one of the five correctly
targeted clones carried the 5’ LoxP site; this frequency
could perhaps be increased by lengthening the 0.5 kb
left arm upstream of the LoxP site. We then generated
Baf57Int/+ and Baf57ΔR/+ mice using standard methods.
The heterozygous pups were born at normal Mendelian
ratios, but homozygous pups were absent, indicating
embryonic lethality. Both strains widely expressed GFP,
with the GFP expression in T cells in Baf57Int/+ mice
abolishable by CD4-Cre, indicating that Baf57Int is
useful for reporting Cre activity (see Additional file 1,
Figure S1). Finally, we generated Baf57F by deleting the
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gene-trap cassette in Baf57Int using a line ubiquitously
expressing FLPe.
Characterization of Baf57F and Baf57ΔR
We first examined Baf57F/+; CD4-Cre mice carrying the
CD4-Cre transgene that directs Cre expression in CD4+
T cells (i.e., DP and CD4 cells) [39]. PCR analysis con-
firmed that the floxed sequence was effectively deleted
from thymocytes (not shown). To determine the status of
the BAF57 protein, we performed western blotting using
an antibody against the C-terminus of BAF57. In both the
thymocytes and CD4 cells from Baf57F/+; CD4-Cre mice,
Cre-mediated deletion led to the emergence of three trun-
cation mutants of BAF57 that were much less abundant
than WT BAF57 (Figure 4A, lanes 2 and 6). The mutants
seemed upregulated in Baf57F/F; CD4-Cre thymocytes
where both copies of Baf57F were subject to deletion
(Figure 4A, lane 3). Of note, a low level of WT BAF57 per-
sisted in total thymocytes from these mice, which presum-
ably came from the DN subset lacking Cre expression. We
next examined Baf57ΔR, alone and in combination with
Baf57F. As expected, Baf57ΔR did not express a mutant
protein detectable by the antibody (Figure 4A, lane 4),
whereas the Baf57F/ΔR; CD4-Cre thymocytes harbored the
three truncation mutants, as well as a trace amount of
WT BAF57 that was less abundant than in Baf57F/F; CD4-
Cre mice (as expected from the fact that the latter carried
two copies of Baf57F (Figure 4A, lane 5). Finally, mature
CD4 cells from Baf57F/ΔR; CD4-Cre mice also expressed
the three truncation mutants, but WT BAF57 was absent
in these cells, indicating complete deletion of the floxed
allele (Figure 4A, lane 7). There was no gross defect in the
development or function of T cells in any of the mice
described above (not shown).
   Flox 
Neo GFP      ΔR
Neo GFP
 Lox  Lox
 Cre
  Flp
     WT
Allele Status Protein Expression




 FRT  FRT Ires
Figure 1 Strategy for green fluorescent protein (GFP)-labeled reversible conditional gene knockout (cKO). This method requires a
conventional floxed allele (Flox) paired with a multi-functional reversible KO (ΔR) allele (top left), and sequential action of Cre and Flp
recombinases (middle and bottom). Depicted are the status of the alleles (left) and the corresponding protein expression patterns (right). SA,
splicing acceptor; Neo, neomycin resistance gene; FRT, Flippase recognition target (red dots).
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To determine whether Baf57ΔR could be conditionally
activated through deletion of the gene-trap cassette, we
used the R26FlpoER1 deleter strain that ubiquitously
expresses FlpoER1 from the Rosa26 locus [40]. FlpoER1 is
a fusion between the codon-optimized FLP called FLPo
[41,42] and the modified estrogen receptor (ER), ERT2,
which retains the recombinase in the cytosol until tamoxi-
fen (TAM) administration [43], with a linker sequence
derived from Cre-ER inserted between the FLPo and ERT2.
In mice carrying Baf57ΔR and expressing FlpoER1, TAM
injection therefore would induce nuclear translocation of
FlpoER1 to cause deletion of the gene-trap cassette and
hence activation of the Baf57ΔR. To determine the ability
of FlpoER1 to activate Baf57ΔR, we introduced R26FlpoER1
into Baf57F/ΔR mice. We injected TAM once a day for 3
consecutive days, and monitored GFP expression in per-
ipheral blood lymphocytes. Before TAM injection,
GFP was uniformly expressed in CD4, CD8 and B cells
(Figure 4C, top middle panel). Cells losing GFP emerged
6 days after the first TAM injection, and comprised
around 50% of total lymphocytes on day 10, when the
GFP signals in the affected cells were reduced by about 4-
fold (Figure 4C, bottom middle plot). Because the GFP
half-life is ~24 hours and the peripheral lymphocytes are
mostly resting, deletion of the gene-trap cassette in our
mice seemed to occur predominantly around day 8 after
the first TAM injection. A similar observation was made
in a Baf57F/ΔR ; CD4-Cre; R26FlpoER1 mouse, except that
on day 10, only about 30% of the lymphocytes had deleted
the gene-trap cassette (Figure 4C, right). The variation in
the deletion efficiency was stochastic and not correlated
with genotype; on average, the deletion efficiencies at day
10 were 37 ± 8%, 37 ± 7%, and 51 ± 8% in CD4, CD8, and
B lymphocytes, respectively (Figure 4D). We sorted GFP+
and GFPlow/- cells from Baf57F/ΔR; CD4-Cre; R26FlpoER1
mice, and performed western blotting. As expected, the
GFP+ cells expressed only the three truncation mutants
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 a       b  c   d
 E2  E3 E4
Neo GFP
 
    57F 





 57Int   

 
       (Reversible)

 
       (Intermediate)

   NdeI
ClaI
EcoR1
         ATG          ATG
E5 E1





Coiled coil (220-280) 
 Acidic 
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Figure 2 Baf57 allelic series produced by a single gene-trap vector. The domain structure of BAF57 is depicted at the top, where the N-terminal
23-residue proline-rich region (P) is encoded by Exons 2 to 4. BAF57 translation normally starts at the ATG in exon 2, but exon 4 (and exon 5) also
contains an ATG that is in frame with the remaining sequence. The targeting vector contains a pair of Flippase recognition target (FRT) sites (red dots)
and a pair of LoxP sites (triangles) flanking the gene-trap cassette. During homologous recombination, crossing over at the left arm can happen
downstream or upstream of the 5’ Lox P site (red vertical lines 1 and 2 flanking the 5’ Lox P site), generating Baf57ΔR and the intermediate Baf57Int
alleles, respectively, the latter convertible to Baf57F, where exons 2 and 3 are floxed. DT, diphtheria toxin expression cassette; HMG, high mobility
group; NHRLI, a domain rich in Asp, His, Leu and Ile; NLS, nuclear localization signal. Green arrows denote PCR primers used in Figure 3A.
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importantly, WT BAF57 was restored in GFPlow/- cells,
showing that Baf57ΔR can indeed be converted into the
WT allele (Figure 4A, lane 8).
We next sought to determine the identities of the
three mutants expressed by Baf57F after Cre-mediated
deletion of exons 2 to 3 (these mutant referred to as
Baf57Δ(2-3) hereafter). As mentioned before, Baf57Δ(2-3)
is expected to direct the expression of the BAF57
mutant that lacks the first 18 residues and hence is
about 2 kDa smaller than the WT protein, which might
account for one of these three mutants, as the molecular
weights of these mutants seemed to differ from the WT
protein by less than 5 kDa. The other two mutants
might be its degradation products, and/or be expressed
from aberrantly spliced transcripts. To address this, we
performed reverse transcriptase (RT)-PCR using primers
targeting exons 1 and 7. The primers amplified a single
product of 839 bp in WT CD4 cells as expected, but
produced two smaller bands from Baf57F/ΔR ; CD4-Cre
mice (Figure 4B, lanes 1 and 2). RT-PCR using primers
targeting exons 1 and 5 suggested that the top and bot-
tom bands in the mutant cells represented the predicted
 
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Figure 3 Identification of embryonic stem (ES) clones bearing Baf57Int and Baf57ΔR. (A) PCR screening for ES clones with correctly
integrated arms. We first used the primer pair a/b (Figure 2) to screen for left-arm integration. Of twenty clones examined, seven gave positive
results; five of these seven clones were confirmed by re-screening (top), and in each of the five clones, the right arm was correctly integrated
based on PCR using primer pair c/d depicted in Figure 2 (bottom). (B) To determine if the 5’ LoxP site is present in these five clones, we
digested the PCR products amplified with the primer set a/b with restriction enzymes recognizing cloning sites at the LoxP site, which showed
that clone 5 carried the 5’ Lox P site and hence the Baf57Int. Of note, an additional EcoR1 site was present within the gene-trapping cassette,
hence there were cleavages in all five amplicons. The 3.4 kb amplicon (Figure 2) is depicted at the bottom, with the approximate positions (in
kb) of the restriction sizes indicated. The green arrows denote PCR primers as in Figure 2. C, ClaI, E, EcoR1, N, NdeI. (C) Southern blotting
confirmed the identities of Baf57Int and Baf57ΔR. The asterisks and arrows indicate the genomic fragments released (by EcoRV digestion) from the
WT and the targeted alleles, respectively. The strategy of the assay is diagrammed at the bottom.
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transcript (with exon 1 joined to exon 4) and an aber-
rant transcript with exon 1 joined to exon 5, respectively
(Figure 4B, lanes 3 and 4), which was confirmed by
restriction enzyme digestion of the amplicons (lanes 5
to 10). Interestingly, exon 5 was also found to harbor an
in-frame ATG, suggesting that the aberrantly spliced
transcript can be translated into a deletion mutant lack-
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Figure 4 Behaviors of Baf57Int and Baf57ΔR. (A) Western blot examining Brg/Brahma-associated factor (BAF)57 expression in total thymocytes
(lanes 1 to 5, and lane 10) and purified CD4 cells (lanes 6 to 9). Samples in lanes 8 to 10 were from mice exposed to TAM. The genotype of the
mice are indicated, where F, ΔR and Flp denote Baf57F, Baf57ΔR and R26FlpoER1, respectively. The bracket at the left indicates the three BAF57
mutant proteins expressed from Baf57F after deletion of floxed sequence. At least three mice of each genotype were analyzed. Shown is a
representative experiment. (B) Reverse transcriptase (RT)-PCR examining BAF57 transcripts in CD4 cells expressed by the wild-type (WT) allele
(lanes 1 and 3) or the mutant allele lacking exons 2 and 3 (lanes 2 and 4); the cells were isolated from Baf57+/ΔR; CD4-Cre; R26FlpoER1 and Baf57F/
ΔR; CD4-Cre; R26FlpoER1 mice, respectively. RT-PCR primers targeted exons 1 and 7 (lanes 1 and 2) or 1 and 5 (lanes 3 and 4). The latter primer set
yielded amplicons A to C (lanes 3 and 4, diagrammed at the bottom), which were re- amplified with a nested primer set, gel-purified, and
digested with EcoN1 to verify their identities (lanes 5 to 10). There was also a nonspecific amplicon (about 310 bp, lane 3) which was not re-
amplifiable (not shown). Two mice of each genotype were analyzed. Shown is a representative experiment. (C). Flow cytometric assays
monitoring green fluorescent protein (GFP) expression in peripheral blood CD4, CD8 and B cells at various times after tamoxifen (TAM) injection.
Three mice of each genotype were analyzed. (D) Summary of the reversion efficiencies at day 10 in CD4, CD8, and B cells, as measured by the
fraction of cells that had lost GFP. Each symbol represents an individual mouse.
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HMG domain) and hence is about 8 kDa smaller than
WT protein. Perhaps this mutant was running aber-
rantly slowly to constitute one of three mutant bands.
Of note, as in the case of the ATG in exon 4, the ATG
in exon 5 is not embedded in the Kozak consensus
sequence, consistent with their low expression levels
compared with the WT protein. Thus, at least two of
the three mutant proteins might result from translation
of spliced transcripts. Indeed, multiple alternatively
spliced transcripts, two of them predicted to direct the
expression of the mutant proteins lacking the N-term-
inal 18 and 70 aa, normally exist in the brain [44]. How-
ever, direct sequencing of these bands is needed to
confirm this hypothesis, particularly because of the unu-
sual mobility of BAF57, whose predicted molecular
weight is 45 kDa but whose apparent molecular weight
ranges from 50 to 57 kDa, depending on the gel system
used.
Finally, as alluded to before, although the three mutant
proteins were expressed, as expected, only at very low
levels in the cells that also expressed WT protein, they
accumulated in the cells lacking the WT protein, which
occurred both in the thymus (Figure 4A, lanes 2 versus 5)
and the mature CD4 cells (Figure 4A, lanes 6 versus 7,
and 8 versus 9). This upregulation of the mutant proteins
in the absence of WT BAF57 presumably reflected a
post-translational regulatory mechanism seeking to main-
tain stoichiometric abundance of various BAF subunits
[45]. As the mutant proteins are at least partially active,
their accumulation may help explain why deletion of the
floxed exons in Baf57F had no major biological effect.
However, because the mutants presumably lacked the
intact N-terminus, their accumulation might recapitulate,
to some extent, the phenotype seen in mice overexpres-
sing a BAF57 dominant-negative mutant lacking the N-
terminal 133 aa, and more importantly, this defect may be
prevented by TAM treatment. This is indeed the case, as
described below.
Phenotype caused by Baf57 mutations and its
prevention by TAM injection
A major defect caused by overexpressing the BAF57
mutant lacking the N-terminal 133 aa is the dramatically
impaired CD8 expression in early DP cells, which is found
in the large thymocyte blasts lacking T-cell receptor
(TCR), CD25 or CD44 expression (designated TCR-CD25-
CD44-FShi) [21,24,34]. In control mice, this early thymo-
cyte population comprised mostly (84%) DP cells and no
CD4+CD8low/- cells, the latter being the hallmark of
impaired CD8 expression (Figure 5, row A, column 2,
where the red circle denotes the absence of CD4+CD8low/-
cells). Heterozygous deletion of the floxed exons in Baf57
had little effect (row B), whereas homozygous deletion (in
Baf57F/F; CD4-Cre mice) led to significant accumulation of
CD4+CD8low/- cells, which made up 17% of the early thy-
mocyte population (Figure 5, row C), although the effect
was two-fold weaker than in previously reported BAF57
dominant-negative mice containing 34% of the CD4+
CD8low/- cells [24]. Interestingly, a single copy of Baf57ΔR
was sufficient to cause a mild defect in CD8 expression
(Figure 5, row D) whereas a single copy of Baf57Δ(2-3) was
not (Figure 5, row B), despite the fact that Baf57Δ(2-3) was
expressed at very low levels if at all (Figure 4A, lane 2).
The cause of this discrepancy is unclear but we have
excluded GFP expression in the former mice as a potential
mechanism (see Additional file 1, Figure S2). Finally, as
expected, Baf57F/ΔR; CD4-Cre mice also had a significant
defect in CD8 expression (Figure 5, row E). Another major
defect caused by overexpressing the BAF57 mutant lacking
the N-terminal 133 aa is premature CD4 de-repression in
DN cells [24,33]. No such defect was seen in Baf57F/F;
CD4-Cre mice, as predicted from the Cre expression pat-
tern, and neither could Baf57ΔR cause this defect, indicat-
ing that BAF57 is haplosufficient for CD4 repression in
DN cells (not shown).
The fact that Baf57F/ΔR; CD4-Cre mice showed a signif-
icant defect in CD8 expression set the stage for testing
the effect of TAM on the phenotype. Given the rapidity
of early T-cell development and the relatively slow
kinetics of Baf57ΔR activation, it is unfeasible for TAM to
‘cure’ the pre-existing phenotype in early DP cells that
exist only transiently, but TAM might be able to activate
Baf57ΔR in the precursors of these transient cells to pre-
vent the subsequent defective CD8 expression in early
DP cells. To test this, we used Baf57F/ΔR; CD4-Cre;
R26FlpoER1 and Baf57F/ΔR; R26FlpoER1 mice, the latter
included because Baf57ΔR alone sufficed to produce a
detectable, albeit weak, defect in CD8 expression. The
mice were exposed to TAM as described above. Unex-
pectedly, on day 10 after the initial TAM injection, only
about 5% of the early thymocytes had lost GFP expres-
sion (Figure 5, rows F to G, column 1), and the same was
true for later thymocytes (not shown), in contrast to the
approximately 37% deletion efficiency in peripheral lym-
phocytes, thus revealing substantial tissue-specificity in
the deletion efficiency in our system. We then examined
early DP cells showing or lacking GFP expression. As
expected, in cells expressing GFP, CD8 expression was
impaired, with the CD4+CD8low/- population comprising
about 10% and 25% of the early thymocytes in Baf57F/;
R26FlpoER1and Baf57F/ΔR; CD4-Cre; R26FlpoER1 mice,
respectively (Figure 5, rows F to G, columns 2). Impor-
tantly, the CD4+CD8low/- population was absent in the
GFP- compartment, demonstrating successful prevention
of the phenotype (Figure 5, rows F to G, column 3). This
effect was dependent on R26FlpoER1 (not shown) and thus
not an artifact resulting from elimination of GFP (see
Additional file 1, Figure S2).
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Discussion
Strengths and limitations of LOFT
LOFT combines pre-existing basic genetic methods into
a straightforward and reliable reversible gene-targeting
method. The method is reliable because its two compo-
nents, Cre-mediated conditional gene targeting and
FLP-mediated reversible gene trapping, are both well
established. It is also simple because the pair of alleles
involved can typically be generated with a single con-
struct. Furthermore, for the genes whose floxed alleles
are already available, only the trapped alleles are needed










    (TCR- CD25-CD44- FShi)




     F/+
     F/+; Cre
     F/F; Cre













     A
     B
     C
     D
     E
     F
     G
1        2        3
Figure 5 Baf57 mutations impaired CD8 expression, which was preventable by tamoxifen (TAM). Thymocytes were stained with T-cell
receptor (TCR) CD4, CD8, CD25 and CD44 antibodies. The early thymocyte population, which are large cells (defined by high forward scatter or
FShi) that lack TCR, CD25 or CD44, were resolved into GFP- and GFP+ subsets (column 1) before analysis of CD4/CD8 expression (columns 2 to 3).
The genotype symbols are as described in Figure 4A. Of note, a CD4- CD8+ population, which made up 12% of the early thymocytes in WT mice
(blue circle in row A, column 2), was absent in Baf57F/F; CD4-Cre mice, and partially depleted by Baf57ΔR, with unknown mechanisms. At least
three mice of each genotype were analyzed. Shown is a representative experiment.
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which simplifies the method. This is an important advan-
tage because floxed alleles for the majority of mouse genes
will become available in the future thanks to concerted
efforts in several countries [46,47]. LOFT is also flexible,
because the two alleles can be used independently for con-
ventional gene targeting, and what is more, the ‘intermedi-
ate allele’ generated can serve as a GFP reporter of Cre
activities. LOFT does require Cre and FLP-deleter lines, but
this should not pose a problem because numerous Cre lines
are already available, as is a mouse line ubiquitously expres-
sing a version of FlpoER that is far more effective than the
one (FlpoER1) used in the current study; the two versions
are identical except for the linker sequence between FLPo
and ER [40]. Finally, LOFT, whose major application is
likely to be reversible cKO, can have other applications such
as reversal of hypomorphic alleles, as we have shown. As
another application, point mutations may be introduced
into the trapped genes to dissect their functions, which is
analogous to the approach for producing conditional point
mutant mice that we previously developed [21], except that
in the previous method, the point mutant is expressed con-
currently with the loss of the WT protein, whereas in the
LOFT method, the two events can happen sequentially. The
sequential occurrence would be essential in addressing, for
example,, the mode of action of P53. Specifically, KO of the
P53 gene is known to cause tumors, which can be sup-
pressed by restoration of P53 expression [1,2]. Surprising, it
was recently found that a P53 point mutant unable to
induce apoptosis, cell-cycle arrest, or senescence retained
the ability to prevent tumorigenesis, presumably as a result
of the ability of the mutant protein to regulate energy meta-
bolism and production of reactive oxygen species [48].
Whether the mutant can also suppress pre-existing tumors
is unclear, and this important question is readily addressable
by expressing the mutant protein in P53 cKO mice. In sum-
mary, LOFT is a straightforward, reliable, simple, and flex-
ible method for both reversible and conventional
(constitutive or conditional) gene targeting, and is readily
adaptable for other applications.
However, there are several limitations to LOFT. First, the
method involves a pair of alleles with the corresponding
pair of recombinases, thus entailing significant amounts of
breeding. Second, the trapped allele is null by default, and
so the gene needs to be haplosufficient for mouse survival.
Third, the method is not suitable for reversing the effect of
deletion of regulatory elements such as enhancers or silen-
cers. Fourth, because LOFT works by combining Cre/Lox
and gene-trapping systems, any limitation in these basic
genetic methods would apply to LOFT. For example, as
mentioned above, if the target gene is not expressed in ES
cells, then ‘targeted trapping’ is not applicable, and conven-
tional methods, which have much lower efficiency, must be
used [38]. Fortunately, over 65% of all protein-coding
genes in the mouse genome are amenable for promoter
trapping in ES cells [49], and the efficiency can be raised to
85% if the binding sites (which can be made removable) for
a transcription factor expressed in ES cells (Oct4) are engi-
neered into the vector [50]. Thus, inefficient conventional
methods should be reserved for only around 15 to 35% of
protein-coding genes. Because conventional methods are
well established, we do not expect unusual problems in
their application to our setting. Another example of the
limitation of LOFT is that if two targeting constructs are
needed to insert the 5’ and 3’ LoxP sites, as in the case of
floxing a large DNA fragment, then creating the allelic ser-
ies in LOFT will accordingly require two constructs.
Furthermore, Cre/FLPo cannot always efficiently delete tar-
get sequences. Indeed, FLPo-catalyzed removal of the gene-
trap cassette at the BAF57 locus was only around 5% in the
thymus by day 10. This problem can be addressed by mon-
itoring the deletion via GFP expression, and by the use of
the new version of conditional FLP ("FlpoER”) that is effi-
cient ‘in any tissue at any time during development or in
the adult’ [40]. With this version of FLP, Joyner and collea-
gues found that a single injection of TAM was sufficient to
induce widespread and efficient deletion of a reporter gene
in the embryos and adults within 4 and 7 days, respectively,
whereas the version used in the current study (FlpoER1)
barely works under this condition [40]. The new enzyme is
expected to make LOFT widely applicable. However, the
old version (FlpoER1), which is efficient in peripheral T
cells but not thymocytes, has a unique advantage for study-
ing developmental programming of T-cell functions. As
mentioned above, such studies entail gene inactivation in
the thymocytes and subsequent reactivation in mature T
cells. As the thymus continues to export T cells into the
periphery in adults, the peripheral T-cell pool would be sig-
nificantly contaminated with the confounding T cells that
have undergone premature reactivation, if FLP is allowed
to work efficiently in the thymocytes. The final limitation
of LOFT involves the fact that most of the floxed alleles
recently generated by the European Conditional Mouse
Mutagenesis (EUCOMM) carry an FRT site outside the
floxed sequence. If these alleles are paired with reversible
KO alleles, interchromosomal recombination can occur
after FLP activation. These recombination events are pre-
sumably too rare to confound data interpretation, unless
they lead to dominant effects such as tumorigenesis. How-
ever, such effects are in themselves interesting, and so the
nuisance may be a blessing in disguise.
Utility of Baf57ΔR and Baf57F
BAF57ΔR is a null allele that can be rescued by deleting
the gene-trap cassette. BAF57ΔR homozygous mice are
apparently embryonic lethal, which precludes the analy-
sis of the effect of BAF57 KO in adult tissues. This pro-
blem may be solved by deleting the gene-trap cassette
(and hence restoring BAF57 expression) in a fraction of
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cells in the embryo, which may rescue the embryo to
produce mosaic adults containing BAF57 KO, Het, and
WT cells, which are distinguishable based on (the level
of) GFP expression. Such mosaic mice will be the source
of cells lacking BAF57.
In contrast to Baf57ΔR, Baf57F was designed to be a con-
ditional hypomorphic allele expressing a deletion mutant
at a low level, following excision of the floxed sequence.
Instead, we detected three truncated proteins that seemed
to result, at least in part, from alternatively spliced tran-
scripts. In addition, although the mutants were indeed
expressed at very low levels in the presence of the allele
expressing WT BAF57, they accumulated in the absence
of WT BAF57. Despite these unexpected changes, homo-
zygous deletion of the floxed exons in DP cells caused a
phenotype resembling, albeit weaker than, that resulting
from overexpressing the BAF57 dominant-negative
mutant lacking the first 133 aa, confirming that Baf57F is a
conditional hypomorphic allele. We are now extending the
analysis to other tissues, by deleting the floxed exons from
the germline. We suspect that the mice lacking the two
exons will be viable, but may display some specific defects.
This allele may thus enable us to interrogate the role of
BAF57 in a way not feasible with any BAF57 null allele,
whether the null is constitutive or conditional. Finally, our
ultimate goal of developing this method is to study the
potential role of BAF57 in epigenetic programming of
mature T cells. Although no gross functional defects in
mature T cells were detected in Baf57F/ΔR; CD4-Cre;
R26FlpoER1 mice, some specific, subtle defects may exist.
Because the mature T cells are resting, it would be possi-
ble to test whether restoring BAF57 expression in these
cells can rescue the pre-existing phenotype, and we are
therefore systematically searching for the putative func-
tional defects in the mature T cells.
Conclusions
Reversible regulation of endogenous genes in mice is
necessary for addressing multiple important biological
questions. We have combined the Cre/Lox and gene-trap
systems to develop LOFT, a reliable and straightforward
reversible cKO method. LOFT lacks the limitations of the
pre-existing reversible gene regulatory systems, and can
also be used to producing traditional constitutive KO and
cKO mice. It offers an advantageous alternative to the
conventional gene-targeting methods.
Methods
DNA construct, embryonic stem cell targeting, and
mouse breeding
The targeting construct (depicted in Figure 2) was based
on the pEZ FRT Lox backbone (a gift of K. Rajewsky).
This plasmid carries the FRT-flanked promoter-Neo
expression cassette, which is in turn flanked by LoxP
sites. The FRT-flanked cassette was replaced by a
synthetic fragment bearing an FRT-flanked splicing
acceptor together with multiple cloning sites. A Neo-
Ires-GFP-SV40 polyA fragment was inserted immediately
downstream of the splicing acceptor to create the gene-
trapping cassette. The left and right arms flanking the
cassette, encompassing BAF57 exons 2 to 3 and exon 4,
respectively, were amplified by PCR from C57B/6 mice.
The cloned DNA was sequenced in its entirety, and no
PCR-introduced error was found. The construct was
electroporated into 129/sv ES cells, and corrected tar-
geted clones were identified by PCR and Southern blots.
The CD4Cre transgenic mice (on C57B/6 background, a
gift of C. Wilson) have been described previously [39].
The effects of the BAF57 dominant-negative mutation or
Brg1 KO on T cell development are robust and observa-
ble on mixed genetic backgrounds [21,24,34]. R26FlpoER1
mice (on C57B/6 background) were a gift from
A. L. Joyner [40]. The primers for screening the ES cells
are shown in Table 1.
Reverse transcriptase PCR
Total RNA was isolated from sorted CD4 cells with
RNAeasy plus (Qiagen) and amplified by a one-step RT-
PCR kit (Qiagen Inc., Valencia, CA, USA). The ampli-
cons were re-amplified by nested PCR, gel-purified, and
digested with EcoN1.
Southern and western blotting
Genomic DNA (10 ug) was digested with EcoRV and run
on a 0.8% agarose gel. The probe was a 1.5 kb PCR pro-
duct amplified with the primer pair shown in Table 1.
For western blotting, 0.3 million cells were run on a gel
(NuPAGE® Novex 4-12% Bis-Tris gel; Invitrogen Corp.,
Carlsbad, CA, USA) in MOPS running buffer using a com-
mercial protein standard (BenchMark™ Prestained Pro-
tein Standard; Invitrogen) as the molecular weight marker.
The membrane was probed with a BAF57 antibody direc-
ted against the C-terminus of BAF57, before re-probing
with an anti-tubulin antibody as loading control. The pri-
mary antibodies were detected using horseradish peroxi-
dase-conjugated secondary antibodies, which were
visualized with enhanced chemiluminescence reagents on
radiography films.
Tamoxifen injection and flow cytometric analysis
TAM solution (20 mg/ml) was prepared by dissolving
200 mg TAM (free base; T5648; Sigma-Aldrich, St Louis,
MO, USA) to 0.5 ml ethanol before adding 9.5 ml auto-
claved peanut oil. The solution was sonicated and stored
at -20°C. To delete the gene-trap cassette, 100 ul of the
solution was injected intraperitoneally into adult BAF57F/
ΔR; Cre; R26R26FlpoER1 mice once a day for 3 consecutive
days. To monitor the effect of TAM, a few drops of
Chaiyachati et al. BMC Biology 2012, 10:96
http://www.biomedcentral.com/1741-7007/10/96
Page 11 of 13
peripheral blood were treated with red blood cell lysis
buffer, and the cells were then stained with anti-CD4-
APC, anti-CD8-PE-Cy7, and anti-B220-PE before flow
cytometric analysis of GFP expression in lymphocytes.
To determine the effects of BAF57 mutation on early T-
cell development, thymocytes were stained with anti-
CD4-APC, anti-CD8-PE-Cy7, anti-CD25-PE, anti-CD44-
FITC and anti-CD3-Pacific blue, and the data, collected
on the flow cytometers (LSRII; BD Biosciences Inc., San
Jose, CA, USA), were analyzed as described previously
[21,24,34].
Additional material
Additional file 1: Supplemental Figures. Figure S1. Baf57int served as
reporter of Cre activity. Peripheral blood lymphocytes were analyzed for
green fluorescent protein (GFP) expression. The genotypes of the mice
are indicated at the top, where Cre represents the CD4Cre transgene
expressing Cre in the double-positive (DP) cells during T-cell
development. CD4 and CD8 cells are progeny of DP cells, and thus had
undergone Cre-mediated excision at Baf57int. Figure S2. GFP expression
did not impair CD8 expression in early double-positive (DP) cells.
Thymocytes from WT mice or transgenic mice carrying a transgene with
wide expression of green fluorescent protein (GFP) were stained with
CD4, CD8, CD25, and CD44 antibodies, and the cells were analyzed
essentially as described previously [21,24,34]. Thymocytes consist of cells
at various stages of development. Among the cells at the earliest stages
were those that lacked T-cell receptor (TCR) expression and are large in
size, as marked by the gate in column 1. The cells in this gate were
mostly CD25-CD44- (column 2). These CD25-CD44- cells, GFP- in WT mice
but GFP+ in transgenic mice as expected (column 3), consisted mostly of
early DP cells (column 4). CD8 expression in these early DP cells were
impaired by Brg/Brahma-associated factor (BAF)57 mutations, but not by
GFP expression.
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